ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases. Using our proprietary discovery platform for targeted (epitope-specific) immunotherapy, ImmusanT is developing a therapy and personalized diagnostics for celiac disease and is expanding to other autoimmune diseases including Type 1 diabetes.
We are now recruiting for clinical trials in celiac disease.
April 4, 2018
ImmusanT Adds Robert J. Perez to Board of Directors
February 6, 2018
ImmusanT to Present at the 2018 BIO CEO & Investor Conference
One Kendall Square
Cambridge, MA 02139